Lanoracopan treatment for paroxysmal nocturnal hemoglobinuria (PNH)
Part of Blood & lymphatic clinical trials.
This trial tests a new drug called lanoracopan for the blood disease PNH. It aims to see if lanoracopan can safely control PNH symptoms and improve blood counts in patients who haven't responded well to other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have a PNH diagnosis and be in one of these situations: newly diagnosed with active breakdown of red blood cells, not responding well to eculizumab or iptacopan, unable to tolerate those drugs, or have completed a prior lanoracopan trial.
- You need to have (or get) vaccinations against meningitis and pneumonia before starting the study, and if you get them within a certain time, you may need antibiotics.
- You cannot have had a bone marrow transplant or splenectomy.
- You cannot have had cancer (except certain skin or cervical cancers) in the past 5 years.
- You cannot have severe kidney, heart, or lung disease that would make the study unsafe.
- You cannot be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an oral medication, iptacopan, for children with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood condition. It aims to see how well the drug works in kids who have not tried anti-C5 therapy or who are switching from it.
This study tests an oral medication (MY008211A) designed to reduce red blood cell destruction in people with paroxysmal nocturnal hemoglobinuria (PNH). The trial aims to see if the drug is safe and effective in improving anemia and lowering markers of disease activity.
This trial tests an experimental RNA drug (ALN-CFB) for people with PNH who still have low red blood cell counts despite taking a C5 inhibitor. The drug aims to block a protein (complement factor B) to improve anemia.
This study tests a new medicine called SLN12140 for people with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder. It aims to see if the drug can help manage the disease and improve symptoms.
This trial tests pegcetacoplan in children (ages 12–17) with paroxysmal nocturnal hemoglobinuria (PNH), a condition that can cause ongoing blood cell breakdown. The goal is to see if the medicine can improve anemia related to PNH.
This study looks at how well iptacopan works for people with PNH (a condition where red blood cells break down too quickly). It is for adults who have never used certain treatments or who have been on other similar medicines.
Hear when a new Paroxysmal Nocturnal Hemoglobinuria, PNH trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.